Kiniksa Pharmaceuticals International, plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KNSA research report →
About the company
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage.
- CEO
- Sanj K. Patel
- IPO
- 2018
- Employees
- 366
- HQ
- London, GL, GB
Price Chart
- Market Cap
- $4.77B
- P/E
- 64.73
- P/S
- 6.32
- P/B
- 8.01
- EV/EBITDA
- 42.61
- Div Yield
- 0.00%
- Gross Margin
- 54.63%
- Op Margin
- 12.36%
- Net Margin
- 9.69%
- ROE
- 13.26%
- ROIC
- 9.56%
- Revenue
- $677.56M · 60.09%
- Net Income
- $59.01M · 236.61%
- EPS
- $0.80 · 233.33%
- Op Income
- $77.22M
- FCF YoY
- 0.00%
- 52W High
- $67.53
- 52W Low
- $26.27
- 50D MA
- $55.78
- 200D MA
- $45.79
- Beta
- 0.07
- Avg Volume
- 821.41K
Get TickerSpark's AI analysis on KNSA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Malkani Dhiraj H | other | 82,600 |
| Jul 1, 26 | Malkani Dhiraj H | other | 14,000 |
| Jul 1, 26 | Malkani Dhiraj H | other | 2,188 |
| Jul 1, 26 | Malkani Dhiraj H | other | 1,307 |
| Jun 29, 26 | Malkani Dhiraj H | other | 0 |
| May 29, 26 | Quart Barry D | other | 2,799 |
| May 29, 26 | Quart Barry D | other | 12,158 |
| May 29, 26 | Quart Barry D | other | 2,026 |
| May 29, 26 | Quart Barry D | other | 2,799 |
| May 29, 26 | Popovits Kimberly J | other | 2,799 |
Our KNSA coverage
Recent articles, reports, and earnings notes.
Want a deeper read on KNSA?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.